Aricept Lawsuit Filed To Force FDA Action On Petition to Ban High Dose

The consumer watchdog group Public Citizen has filed a lawsuit against the FDA, seeking to force the federal drug regulatory agency to act on a petition filed to recall approval for high doses of Aricept, a medication for treatment of Alzheimer’s disease. 

The Aricept lawsuit was filed on September 5, asking a federal court to force the FDA to respond to Public Citizen’s petition, which was filed in May 2011.

The group asked the FDA to ban 23 milligram doses of Aricept and require new warnings on lower doses of the drug, due to the risk of serious and potentially life-threatening side effects. The complaint was filed because the FDA has taken no action on the petition to date.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

“A primary function of the FDA is to protect citizens from harm caused by needlessly dangerous drugs, in this case a drug no more effective but significantly more dangerous than the lower doses of Aricept,” Public Citizen’s Health Research Group Director Dr. Sidney Wolfe said in a press release. “By ignoring Public Citizen’s petition for more than a year, the agency has ignored this responsibility and instead has chosen to support the profit interests of a large pharmaceutical company.”

According to Public Citizen, the side effects of Aricept in the 23 mg dose are far more toxic than at lower doses. In addition, there appears to be little clinical benefit from using the higher doses over the lower ones.

High doses of Aricept have been linked to a number of potential health risks, including lowered pulse, nausea, vomiting, diarrhea, urinary incontinence, fatigue, dizziness, agitation, confusion and anorexia, the group claims.

Only one clinical trial for 23 mg Aricept has been submitted to the FDA and Public Citizen notes that it failed to show that the 23 mg version was more effective than lower doses. In three out of four tests, there was no significant difference between the 10 mg and 23 mg doses in patients’ cognitive or functional level, and on the fourth test the difference was about 2 points on a scale of 100, which Wolfe says is not clinically important.

Aricept (donepezil) was developed by Pfizer and Eisai and was first approved for the treatment of Alzheimer’s disease in 1996. The 23 mg Aricept treatment was approved by the FDA over the objections of some of its own reviewers in 2010.

Image Credit: |


  • carolFebruary 20, 2023 at 4:59 pm

    real bad medicine

  • ReginaDecember 22, 2014 at 4:51 am

    I need to find out how dangerous it is to be taking 30 mg. Of this drug per day. Thank you!

  • WJAddieJune 30, 2014 at 2:28 pm

    My mother was very aware of what was going on and was able to get around and take care of herself but she started becoming a little forgetful and her new doctor placed on aricept and within a 3 months time period she stopped walking started, hallucinating and ended up in a nursing home where she died shortly after being placed on aricpet.

  • OradeenSeptember 14, 2013 at 10:16 pm

    My mom was given aricept, now her mental mind is gone. She is 75 years old and should of never been given the medicine in the first place.

  • TerryDecember 30, 2012 at 9:36 am

    I was prescribed Aricept for years because my doctor said I had Alzheimers. I ended up in Psych Ward and Nursing Home (due to aricept) , because I did NOT have Alzheimer's. I was DIABETIC. I found out recently that ARICEPT SHOULD NEVER BE GIVEN TO DIABETICS. CAUSES ACETYLCHOLINE OVERLOAD!

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks
Johnson & Johnson Faces Medical Monitoring Lawsuit Over Future Baby Powder Cancer Risks (Posted today)

Women who used Johnson's Baby Powder around their genitals for feminine hygiene purposes now live in fear of developing ovarian cancer, according to the class action lawsuit seeking medical monitoring for future diagnoses

More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing
More Than 9,600 Join Suboxone Lawsuit Over Tooth Decay in MDL Filing (Posted yesterday)

A bundled complaint of about 9,600 Suboxone lawsuits were filed in federal court on Friday, ahead of the two-year anniversary of the FDA requiring tooth decay label warnings on the opioid treatment film strips, which is also a deadline for filing a civil complaint in many states.